BRIEF — US FDA Approves Nogapendekin Alfa Inbakicept — Pmln For BCG — Unresponsive NMIBC On Oct 14, 2026

Oct 14 (Reuters) — FDA: Us Fda - Approves Nogapendekin Alfa Inbakicept-pmln For Bcg-unresponsive Nmibc On Oct 14, 2026 Us Fda - Expands Indication For Nogapendekin Alfa Inbakicept-pmln To High-grade Papillary-only Nmibc Us Fda - Recommended Dose For Nogapendekin Alfa Inbakicept-pmln Is 400 Mcg With Bcg Weekly For 6 Weeks As Induction Therapy Further company coverage: IBRX.O (Reporting by Zakia Mariyam) ((Zakia.Mariyam@thomsonreuters.com;)